Related Experiment Video
Updated: May 20, 2025

Preparation of Enantiopure Non-Activated Aziridines and Synthesis of Biemamide B, D, and epiallo-Isomuscarine
Published on: June 13, 2022
Racemic drugs are not necessarily less efficacious and less safe than their single-enantiomer components
Israel Agranat1, Ilaria D'Acquarica2
1Organic Chemistry, Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Jerusalem 9190401, Israel.
Chiral drug development should prioritize racemates unless a single enantiomer shows a distinct advantage. Recent claims favoring single enantiomers over racemates are challenged, advocating for a case-by-case evaluation.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Drug Development
Background:
- Chiral drugs present a development dilemma: racemate versus single enantiomer.
- Recent publications (2024) claim single enantiomers offer superior clinical potency, efficacy, and safety compared to racemates.
- These claims necessitate a critical re-evaluation of current chiral drug development strategies.
Purpose of the Study:
- To rebut recent allegations favoring single enantiomer drugs over racemates.
- To provide a historical perspective on the development of single enantiomer drugs.
- To analyze cases where racemates or diastereomeric mixtures are preferred over single enantiomers.
Main Methods:
- Historical survey of motivations for single enantiomer drug development.
- Case study analysis of racemate/diastereomeric mixture preference over single enantiomers.
- Examination of 'teaching away' cases from chiral switches (e.g., in vivo interconversion, enantiomerization).
Main Results:
- Racemate/diastereomeric mixture drugs are not inherently less efficacious or safe than single enantiomer components.
- Specific scenarios exist where racemates are preferred, including rapid in vivo interconversion or enantiomerization.
- Advantages and disadvantages of both racemic and single enantiomer drugs are detailed.
Conclusions:
- Racemate/diastereomeric mixture drugs remain viable candidates for chiral switches.
- Development of chiral drugs should proceed with the racemate by default.
- A single enantiomer should only be pursued if a relevant, differentiated property is identified.
Related Concept Videos
Racemic Mixtures and the Resolution of Enantiomers
Properties of Enantiomers and Optical Activity
Chirality in Nature
Stereoisomers
Dose-Response Relationship: Potency and Efficacy
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

